APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide-based Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide-based Drug Market Outlook and Growth Opportunities 2026

2 January 2026196 pages

Choose your research edition.

Industry ResearchPeptide-based Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide-based Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Peptide-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide-based Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide-based Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Peptide-based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide-based Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide-based Drug market include Takeda, Teva, Sanofi, J & J, Novartis, Merck, Eli Lilly, AbbVie and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Peptide-based Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide-based Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide-based Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Peptide-based Drug market.

Peptide-based Drug Segment by Company

Takeda

Teva

Sanofi

J & J

Novartis

Merck

Eli Lilly

AbbVie

AstraZeneca

The Medicines

Novo Nordisk

Ipsen

Ferring

Peptide-based Drug Segment by Type

Injection

Oral

Other

Peptide-based Drug Segment by Application

Cancer

Metabolic Disorders

Central Nervous System

Other

Peptide-based Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Peptide-based Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Peptide-based Drug key companies, revenue, market share, and recent developments.

3. To split the Peptide-based Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Peptide-based Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide-based Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide-based Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide-based Drug industry.

Chapter 3: Detailed analysis of Peptide-based Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Peptide-based Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Peptide-based Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide-based Drug Industry Trends Table 2. Peptide-based Drug Industry Drivers Table 3. Peptide-based Drug Industry Opportunities and Challenges Table 4. Peptide-based Drug Industry Restraints Table 5. Global Peptide-based Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide-based Drug Revenue Share by Company (2021-2026) Table 7. Global Peptide-based Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Peptide-based Drug Key Company Manufacturing Base & Headquarters Table 9. Global Peptide-based Drug Company, Product Type & Application Table 10. Global Peptide-based Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Peptide-based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Injection Table 15. Significant Companies of Oral Table 16. Significant Companies of Other Table 17. Global Peptide-based Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Peptide-based Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Peptide-based Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Peptide-based Drug Sales Value Share by Type (2021-2026) Table 21. Global Peptide-based Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Cancer Table 23. Significant Companies of Metabolic Disorders Table 24. Significant Companies of Central Nervous System Table 25. Significant Companies of Other Table 26. Global Peptide-based Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Peptide-based Drug Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Peptide-based Drug Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Peptide-based Drug Sales Value Share by Application (2021-2026) Table 30. Global Peptide-based Drug Sales Value Share by Application (2027-2032) Table 31. Global Peptide-based Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Peptide-based Drug Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Peptide-based Drug Sales Value Share by Region (2021-2026) Table 34. Global Peptide-based Drug Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Peptide-based Drug Sales Value Share by Region (2027-2032) Table 36. Global Peptide-based Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Peptide-based Drug Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Peptide-based Drug Sales Value Market Share by Country (2021-2026) Table 39. Global Peptide-based Drug Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Peptide-based Drug Sales Value Market Share by Country (2027-2032) Table 41. Takeda Company Information Table 42. Takeda Business Overview Table 43. Takeda Peptide-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Takeda Peptide-based Drug Product Portfolio Table 45. Takeda Recent Development Table 46. Teva Company Information Table 47. Teva Business Overview Table 48. Teva Peptide-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Teva Peptide-based Drug Product Portfolio Table 50. Teva Recent Development Table 51. Sanofi Company Information Table 52. Sanofi Business Overview Table 53. Sanofi Peptide-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Sanofi Peptide-based Drug Product Portfolio Table 55. Sanofi Recent Development Table 56. J & J Company Information Table 57. J & J Business Overview Table 58. J & J Peptide-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. J & J Peptide-based Drug Product Portfolio Table 60. J & J Recent Development Table 61. Novartis Company Information Table 62. Novartis Business Overview Table 63. Novartis Peptide-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Novartis Peptide-based Drug Product Portfolio Table 65. Novartis Recent Development Table 66. Merck Company Information Table 67. Merck Business Overview Table 68. Merck Peptide-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Merck Peptide-based Drug Product Portfolio Table 70. Merck Recent Development Table 71. Eli Lilly Company Information Table 72. Eli Lilly Business Overview Table 73. Eli Lilly Peptide-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Eli Lilly Peptide-based Drug Product Portfolio Table 75. Eli Lilly Recent Development Table 76. AbbVie Company Information Table 77. AbbVie Business Overview Table 78. AbbVie Peptide-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. AbbVie Peptide-based Drug Product Portfolio Table 80. AbbVie Recent Development Table 81. AstraZeneca Company Information Table 82. AstraZeneca Business Overview Table 83. AstraZeneca Peptide-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. AstraZeneca Peptide-based Drug Product Portfolio Table 85. AstraZeneca Recent Development Table 86. The Medicines Company Information Table 87. The Medicines Business Overview Table 88. The Medicines Peptide-based Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. The Medicines Peptide-based Drug Product Portfolio Table 90. The Medicines Recent Development Table 91. Novo Nordisk Company Information Table 92. Novo Nordisk Business Overview Table 93. Novo Nordisk Peptide-based Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Novo Nordisk Peptide-based Drug Product Portfolio Table 95. Novo Nordisk Recent Development Table 96. Ipsen Company Information Table 97. Ipsen Business Overview Table 98. Ipsen Peptide-based Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Ipsen Peptide-based Drug Product Portfolio Table 100. Ipsen Recent Development Table 101. Ferring Company Information Table 102. Ferring Business Overview Table 103. Ferring Peptide-based Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Ferring Peptide-based Drug Product Portfolio Table 105. Ferring Recent Development Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Peptide-based Drug Product Image Figure 2. Global Peptide-based Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide-based Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Injection Image Figure 8. Oral Image Figure 9. Other Image Figure 10. Global Peptide-based Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Peptide-based Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Peptide-based Drug Sales Value Share by Type (2021-2032) Figure 13. Cancer Image Figure 14. Metabolic Disorders Image Figure 15. Central Nervous System Image Figure 16. Other Image Figure 17. Global Peptide-based Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Peptide-based Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Peptide-based Drug Sales Value Share by Application (2021-2032) Figure 20. Global Peptide-based Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Peptide-based Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Peptide-based Drug Sales Value (2021-2032) & (US$ Million) Figure 23. North America Peptide-based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Peptide-based Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Peptide-based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Peptide-based Drug Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Peptide-based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Peptide-based Drug Sales Value (2021-2032) & (US$ Million) Figure 29. South America Peptide-based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Peptide-based Drug Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Peptide-based Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Peptide-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Peptide-based Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Peptide-based Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
  • Other
Applications
  • Cancer
  • Metabolic Disorders
  • Central Nervous System
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • J & J
  • Novartis
  • Merck
  • Eli Lilly
  • AbbVie
  • AstraZeneca
  • The Medicines
  • Novo Nordisk
  • Ipsen
  • Ferring

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide-based Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide-based Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Peptide-based Drug Market Dynamics
  1. 2.1 Peptide-based Drug Industry Trends
  2. 2.2 Peptide-based Drug Industry Drivers
  3. 2.3 Peptide-based Drug Industry Opportunities and Challenges
  4. 2.4 Peptide-based Drug Industry Restraints
3 Peptide-based Drug Market by Company
  1. 3.1 Global Peptide-based Drug Company Revenue Ranking in 2025
  2. 3.2 Global Peptide-based Drug Revenue by Company (2021-2026)
  3. 3.3 Global Peptide-based Drug Company Ranking (2024-2026)
  4. 3.4 Global Peptide-based Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Peptide-based Drug Company Product Type and Application
  6. 3.6 Global Peptide-based Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Peptide-based Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Peptide-based Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Peptide-based Drug Market by Type
  1. 4.1 Peptide-based Drug Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Oral
  4. 4.1.3 Other
  5. 4.2 Global Peptide-based Drug Sales Value by Type
  6. 4.2.1 Global Peptide-based Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Peptide-based Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Peptide-based Drug Sales Value Share by Type (2021-2032)
5 Peptide-based Drug Market by Application
  1. 5.1 Peptide-based Drug Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Metabolic Disorders
  4. 5.1.3 Central Nervous System
  5. 5.1.4 Other
  6. 5.2 Global Peptide-based Drug Sales Value by Application
  7. 5.2.1 Global Peptide-based Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Peptide-based Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Peptide-based Drug Sales Value Share by Application (2021-2032)
6 Peptide-based Drug Regional Value Analysis
  1. 6.1 Global Peptide-based Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide-based Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Peptide-based Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Peptide-based Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide-based Drug Sales Value (2021-2032)
  7. 6.3.2 North America Peptide-based Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Peptide-based Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Peptide-based Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Peptide-based Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Peptide-based Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Peptide-based Drug Sales Value (2021-2032)
  16. 6.6.2 South America Peptide-based Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Peptide-based Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Peptide-based Drug Sales Value Share by Country, 2025 VS 2032
7 Peptide-based Drug Country-level Value Analysis
  1. 7.1 Global Peptide-based Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide-based Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Peptide-based Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Peptide-based Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Peptide-based Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Peptide-based Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Peptide-based Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Peptide-based Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Peptide-based Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Peptide-based Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Peptide-based Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Peptide-based Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Peptide-based Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Peptide-based Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Peptide-based Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Peptide-based Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Peptide-based Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Peptide-based Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Peptide-based Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Peptide-based Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Peptide-based Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Peptide-based Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Peptide-based Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Peptide-based Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Peptide-based Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Peptide-based Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Peptide-based Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Peptide-based Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Peptide-based Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Peptide-based Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Peptide-based Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Peptide-based Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Peptide-based Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Peptide-based Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Peptide-based Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Peptide-based Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Peptide-based Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Peptide-based Drug Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Peptide-based Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Peptide-based Drug Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 J & J
  20. 8.4.1 J & J Company Information
  21. 8.4.2 J & J Business Overview
  22. 8.4.3 J & J Peptide-based Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 J & J Peptide-based Drug Product Portfolio
  24. 8.4.5 J & J Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Peptide-based Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Peptide-based Drug Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Peptide-based Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Peptide-based Drug Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Peptide-based Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Peptide-based Drug Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 AbbVie
  44. 8.8.1 AbbVie Company Information
  45. 8.8.2 AbbVie Business Overview
  46. 8.8.3 AbbVie Peptide-based Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Peptide-based Drug Product Portfolio
  48. 8.8.5 AbbVie Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Peptide-based Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Peptide-based Drug Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 The Medicines
  56. 8.10.1 The Medicines Company Information
  57. 8.10.2 The Medicines Business Overview
  58. 8.10.3 The Medicines Peptide-based Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 The Medicines Peptide-based Drug Product Portfolio
  60. 8.10.5 The Medicines Recent Developments
  61. 8.11 Novo Nordisk
  62. 8.11.1 Novo Nordisk Company Information
  63. 8.11.2 Novo Nordisk Business Overview
  64. 8.11.3 Novo Nordisk Peptide-based Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novo Nordisk Peptide-based Drug Product Portfolio
  66. 8.11.5 Novo Nordisk Recent Developments
  67. 8.12 Ipsen
  68. 8.12.1 Ipsen Company Information
  69. 8.12.2 Ipsen Business Overview
  70. 8.12.3 Ipsen Peptide-based Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Ipsen Peptide-based Drug Product Portfolio
  72. 8.12.5 Ipsen Recent Developments
  73. 8.13 Ferring
  74. 8.13.1 Ferring Company Information
  75. 8.13.2 Ferring Business Overview
  76. 8.13.3 Ferring Peptide-based Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ferring Peptide-based Drug Product Portfolio
  78. 8.13.5 Ferring Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst